Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 186, Issue 1-2, Pages 86-93Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2007.03.014
Keywords
PECAM-1; EAE; sPECAM-Fc; MS; cellular migration
Categories
Funding
- NHLBI NIH HHS [HL046849, R01 HL046849] Funding Source: Medline
- NINDS NIH HHS [R01 NS037570-05A1, R01 NS037570, R56 NS037570, R01 NS37570-01, R01 NS037570-06] Funding Source: Medline
Ask authors/readers for more resources
The homophilic cell adhesion molecule PECAM-1 is a major participant in the migration of leukocytes across endothelium. We examined the ability of a chimeric soluble PECAM-1 fused to human IgG-Fc to impair leukocyte entry through the blood-brain barrier and reduce CNS autoimmunity. sPECAM-Fc impaired migration of lymphocytes across brain endothelial monolayers and diminished the severity of EAE, an experimental model of MS, when administered at the onset of symptoms. However, in mice transgenic for sPECAM-Fc, the chronically elevated levels of sPECAM-Fc hastened onset of EAE. disease without significantly changing clinical score severity. Our data suggest that short-term treatment of diseases like MS with sPECAM-Fc has therapeutic potential. (c) 2007 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available